Johnson & Johnson (JNJ)'s Zytiga Helps Eliminate Early-Stage Prostate Cancer
5/17/2012 7:44:04 AM
Johnson & Johnson (JNJ)’s Zytiga, approved last year to treat metastatic prostate cancer, helped eliminate tumors in high-risk patients whose malignancy hadn’t yet spread, a small study found. The pill was given as an initial therapy before surgery to 58 patients with aggressive tumors that were confined to the prostate gland, a group typically treated with radiation. These patients are rarely cured by surgery and previous studies using older drugs failed to improve survival, said Mary-Ellen Taplin, an associate professor at Harvard Medical School in Boston.